Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 2—February 2020
Research

Exposure to Ebola Virus and Risk for Infection with Malaria Parasites, Rural Gabon

Jessica L. AbbateComments to Author , Pierre Becquart, Eric Leroy, Vanessa O. Ezenwa1, and Benjamin Roche1
Author affiliations: Institut de Recherche pour le Développement, Unité Mixte de Recherche MIVEGEC, Montpellier, France (J.L. Abbate, P. Becquart, E. Leroy, B. Roche); Institut de Recherche pour le Développement, Unité Mixte Internationale UMMISCO, Bondy, France (J.L. Abbate, B. Roche); CIRMF, Franceville, Gabon (E. Leroy); University of Georgia, Athens, Georgia, USA (V.O. Ezenwa); Universidad National Autonoma de Mexico, Mexico City, Mexico (B. Roche)

Main Article

Figure 2

Association of Ebola virus exposure and Plasmodium spp. infection across rural communities in Gabon. A) Geographic distribution of Ebola virus antibody seroprevalence. B) Geographic distribution of malaria parasite (all Plasmodium species) prevalence. C) Correlation between these geographic distributions at the level of administrative department (ρ = 0.43, p<0.01). The fitted curve and 95% CIs (gray shading) were generated by using the predict function from the basic stats package in the R ve

Figure 2. Association of Ebola virus exposure and Plasmodium spp. infection across rural communities in Gabon. A) Geographic distribution of Ebola virus antibody seroprevalence. B) Geographic distribution of malaria parasite (all Plasmodium species) prevalence. C) Correlation between these geographic distributions at the level of administrative department (ρ = 0.43, p<0.01). The fitted curve and 95% CIs (gray shading) were generated by using the predict function from the basic stats package in the R version 3.2.2 statistical programming environment (23), based on a linear model between the 2 variables weighted by the number of persons sampled in each department.

Main Article

References
  1. Hartley  M-A, Young  A, Tran  A-M, Okoni-Williams  HH, Suma  M, Mancuso  B, et al. Predicting Ebola severity: a clinical prioritization score for Ebola virus disease. PLoS Negl Trop Dis. 2017;11:e0005265. DOIPubMedGoogle Scholar
  2. Barry  M, Traoré  FA, Sako  FB, Kpamy  DO, Bah  EI, Poncin  M, et al. Ebola outbreak in Conakry, Guinea: epidemiological, clinical, and outcome features. Med Mal Infect. 2014;44:491–4. DOIPubMedGoogle Scholar
  3. Waxman  M, Aluisio  AR, Rege  S, Levine  AC. Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study. Lancet Infect Dis. 2017;17:654–60. DOIPubMedGoogle Scholar
  4. Gignoux  E, Azman  AS, de Smet  M, Azuma  P, Massaquoi  M, Job  D, et al. Effect of artesunate-amodiaquine on mortality related to Ebola virus disease. N Engl J Med. 2016;374:23–32. DOIPubMedGoogle Scholar
  5. Carroll  MW, Haldenby  S, Rickett  NY, Pályi  B, Garcia-Dorival  I, Liu  X, et al. Deep sequencing of RNA from blood and oral swab samples reveals the presence of nucleic acid from a number of pathogens in patients with acute Ebola virus disease and is consistent with bacterial translocation across the gut. MSphere. 2017;2:e00325–17. DOIPubMedGoogle Scholar
  6. Rosenke  K, Adjemian  J, Munster  VJ, Marzi  A, Falzarano  D, Onyango  CO, et al. Plasmodium parasitemia associated with increased survival in Ebola virus-infected patients. Clin Infect Dis. 2016;63:1026–33. DOIPubMedGoogle Scholar
  7. Walker  PGT, White  MT, Griffin  JT, Reynolds  A, Ferguson  NM, Ghani  AC. Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis. Lancet Infect Dis. 2015;15:825–32. DOIPubMedGoogle Scholar
  8. Takahashi  S, Metcalf  CJE, Ferrari  MJ, Moss  WJ, Truelove  SA, Tatem  AJ, et al. Reduced vaccination and the risk of measles and other childhood infections post-Ebola. Science. 2015;347:1240–2. DOIPubMedGoogle Scholar
  9. Parpia  AS, Ndeffo-Mbah  ML, Wenzel  NS, Galvani  AP. Effects of response to 2014–2015 Ebola outbreak on deaths from malaria, HIV/AIDS, and tuberculosis, West Africa. Emerg Infect Dis. 2016;22:433–41. DOIPubMedGoogle Scholar
  10. Vetter  P, Kaiser  L, Schibler  M, Ciglenecki  I, Bausch  DG. Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis. 2016;16:e82–91. DOIPubMedGoogle Scholar
  11. World Health Organization. World Malaria Report 2017 [cited 2019 Dec 5) http://apps.who.int/iris/bitstream/10665/259492/1/9789241565523-eng.pdf
  12. Hay  SI, Guerra  CA, Gething  PW, Patil  AP, Tatem  AJ, Noor  AM, et al. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med. 2009;6:e1000048. DOIPubMedGoogle Scholar
  13. Pourrut  X, Kumulungui  B, Wittmann  T, Moussavou  G, Délicat  A, Yaba  P, et al. The natural history of Ebola virus in Africa. Microbes Infect. 2005;7:1005–14. DOIPubMedGoogle Scholar
  14. Munster  VJ, Bausch  DG, de Wit  E, Fischer  R, Kobinger  G, Muñoz-Fontela  C, et al. Outbreaks in a rapidly changing Central Africa—lessons from Ebola. N Engl J Med. 2018;379:1198–201. DOIPubMedGoogle Scholar
  15. Mbala-Kingebeni  P, Aziza  A, Di Paola  N, Wiley  MR, Makiala-Mandanda  S, Caviness  K, et al. Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment. Lancet Infect Dis. 2019;19:648–57. DOIPubMedGoogle Scholar
  16. Glennon  EE, Jephcott  FL, Restif  O, Wood  JLN. Estimating undetected Ebola spillovers. PLoS Negl Trop Dis. 2019;13:e0007428. DOIPubMedGoogle Scholar
  17. Becquart  P, Wauquier  N, Mahlakõiv  T, Nkoghe  D, Padilla  C, Souris  M, et al. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One. 2010;5:e9126. DOIPubMedGoogle Scholar
  18. Nkoghe  D, Padilla  C, Becquart  P, Wauquier  N, Moussavou  G, Akué  JP, et al. Risk factors for Zaire ebolavirus—specific IgG in rural Gabonese populations. J Infect Dis. 2011;204(Suppl 3):S768–75. DOIPubMedGoogle Scholar
  19. Délicat-Loembet  L, Rougeron  V, Ollomo  B, Arnathau  C, Roche  B, Elguero  E, et al. No evidence for ape Plasmodium infections in humans in Gabon. PLoS One. 2015;10:e0126933. DOIPubMedGoogle Scholar
  20. Akue  JP, Nkoghe  D, Padilla  C, Moussavou  G, Moukana  H, Mbou  RA, et al. Epidemiology of concomitant infection due to Loa loa and Mansonella perstans in Gabon. PLoS Negl Trop Dis. 2011;5:e1329. DOIPubMedGoogle Scholar
  21. Délicat-Loembet  LM, Elguero  E, Arnathau  C, Durand  P, Ollomo  B, Ossari  S, et al. Prevalence of the sickle cell trait in Gabon: a nationwide study. Infect Genet Evol. 2014;25:52–6. DOIPubMedGoogle Scholar
  22. Demographic and Health Surveys Program. Survey summary: Gabon: standard DHS 2012 [cited 2019 Dec 5]. http://www.measuredhs.com/what-we-do/survey/survey-display-402.cfm
  23. R Core Team. R: a language and environment for statistical computing [cited 2019 Aug 14]. https://www.r-project.org
  24. Sakurai  Y, Sakakibara  N, Toyama  M, Baba  M, Davey  RA. Novel amodiaquine derivatives potently inhibit Ebola virus infection. Antiviral Res. 2018;160:175–82. DOIPubMedGoogle Scholar
  25. Madrid  PB, Chopra  S, Manger  ID, Gilfillan  L, Keepers  TR, Shurtleff  AC, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One. 2013;8:e60579. DOIPubMedGoogle Scholar
  26. Zilbermintz  L, Leonardi  W, Jeong  S-Y, Sjodt  M, McComb  R, Ho  C-LC, et al. Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting. Sci Rep. 2015;5:13476. DOIPubMedGoogle Scholar
  27. Clark  DV, Kibuuka  H, Millard  M, Wakabi  S, Lukwago  L, Taylor  A, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis. 2015;15:905–12. DOIPubMedGoogle Scholar
  28. Etard  J-F, Sow  MS, Leroy  S, Touré  A, Taverne  B, Keita  AK, et al.; Postebogui Study Group. Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infect Dis. 2017;17:545–52. DOIPubMedGoogle Scholar
  29. Lanini  S, Portella  G, Vairo  F, Kobinger  GP, Pesenti  A, Langer  M, et al.; INMI-EMERGENCY EBOV Sierra Leone Study Group. Relationship between viremia and specific organ damage in Ebola patients: a cohort study. Clin Infect Dis. 2018;66:36–44. DOIPubMedGoogle Scholar
  30. Davis  TME, Pongponratan  E, Supanaranond  W, Pukrittayakamee  S, Helliwell  T, Holloway  P, et al. Skeletal muscle involvement in falciparum malaria: biochemical and ultrastructural study. Clin Infect Dis. 1999;29:831–5. DOIPubMedGoogle Scholar
  31. World Health Organization. Malaria control campaign launched in Democratic Republic of the Congo to save lives and aid Ebola response [cited 2019 May 3]. https://www.afro.who.int/news/malaria-control-campaign-launched-democratic-republic-congo-save-lives-and-aid-ebola-response
  32. Wauquier  N, Becquart  P, Gasquet  C, Leroy  EM. Immunoglobulin G in Ebola outbreak survivors, Gabon. Emerg Infect Dis. 2009;15:1136–7. DOIPubMedGoogle Scholar
  33. Busico  KM, Marshall  KL, Ksiazek  TG, Roels  TH, Fleerackers  Y, Feldmann  H, et al. Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179(Suppl 1):S102–7. DOIPubMedGoogle Scholar
  34. Gonzalez  JP, Nakoune  E, Slenczka  W, Vidal  P, Morvan  JM. Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic. Microbes Infect. 2000;2:39–44. DOIPubMedGoogle Scholar
  35. Gonzalez  JP, Josse  R, Johnson  ED, Merlin  M, Georges  AJ, Abandja  J, et al. Antibody prevalence against haemorrhagic fever viruses in randomized representative Central African populations. Res Virol. 1989;140:319–31. DOIPubMedGoogle Scholar
  36. Steffen  I, Lu  K, Yamamoto  LK, Hoff  NA, Mulembakani  P, Wemakoy  EO, et al. Serologic prevalence of Ebola virus in equatorial Africa. Emerg Infect Dis. 2019;25:911–8. DOIPubMedGoogle Scholar
  37. Allela  L, Boury  O, Pouillot  R, Délicat  A, Yaba  P, Kumulungui  B, et al. Ebola virus antibody prevalence in dogs and human risk. Emerg Infect Dis. 2005;11:385–90. DOIPubMedGoogle Scholar
  38. Lanini  S, Portella  G, Vairo  F, Kobinger  GP, Pesenti  A, Langer  M, et al.; INMI-EMERGENCY EBOV Sierra Leone Study Group. Blood kinetics of Ebola virus in survivors and nonsurvivors. J Clin Invest. 2015;125:4692–8. DOIPubMedGoogle Scholar
  39. de La Vega  MA, Caleo  G, Audet  J, Qiu  X, Kozak  RA, Brooks  JI, et al. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest. 2015;125:4421–8. DOIPubMedGoogle Scholar
  40. Glynn  JR, Bower  H, Johnson  S, Houlihan  CF, Montesano  C, Scott  JT, et al. Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus. Lancet Infect Dis. 2017;17:645–53. DOIPubMedGoogle Scholar
  41. Caron  A, Bourgarel  M, Cappelle  J, Liégeois  F, De Nys  HM, Roger  F. Ebola virus maintenance: if not (only) bats, what else? Viruses. 2018;10:E549. DOIPubMedGoogle Scholar
  42. De Nys  HM, Kingebeni  PM, Keita  AK, Butel  C, Thaurignac  G, Villabona-Arenas  C-J, et al. Survey of Ebola viruses in frugivorous and insectivorous bats in Guinea, Cameroon, and the Democratic Republic of the Congo, 2015–2017. Emerg Infect Dis. 2018;24:2228–40. DOIPubMedGoogle Scholar
  43. Rowe  AK, Bertolli  J, Khan  AS, Mukunu  R, Muyembe-Tamfum  JJ, Bressler  D, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis. 1999;179(Suppl 1):S28–35. DOIPubMedGoogle Scholar
  44. Leroy  EM, Baize  S, Volchkov  VE, Fisher-Hoch  SP, Georges-Courbot  MC, Lansoud-Soukate  J, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000;355:2210–5. DOIPubMedGoogle Scholar
  45. Macneil  A, Reed  Z, Rollin  PE. Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis. 2011;5:e1175. DOIPubMedGoogle Scholar
  46. Baird  JK. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol Today. 1995;11:105–11. DOIPubMedGoogle Scholar
  47. Fenton  A, Knowles  SCL, Petchey  OL, Pedersen  AB. The reliability of observational approaches for detecting interspecific parasite interactions: comparison with experimental results. Int J Parasitol. 2014;44:437–45. DOIPubMedGoogle Scholar
  48. Henao-Restrepo  AM, Camacho  A, Longini  IM, Watson  CH, Edmunds  WJ, Egger  M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389:505–18. DOIPubMedGoogle Scholar
  49. Shiwani  HA, Pharithi  RB, Khan  B, Egom  CBA, Kruzliak  P, Maher  V, et al. An update on the 2014 Ebola outbreak in western Africa. Asian Pac J Trop Med. 2017;10:6–10. DOIPubMedGoogle Scholar
  50. Bellan  SE, Pulliam  JRC, Dushoff  J, Meyers  LA. Ebola control: effect of asymptomatic infection and acquired immunity. Lancet. 2014;384:1499–500. DOIPubMedGoogle Scholar

Main Article

1These senior authors contributed equally to this article.

Page created: January 17, 2020
Page updated: January 17, 2020
Page reviewed: January 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external